If you are considering Spravato (esketamine) for treatment-resistant depression, it’s natural to want to know what the schedule will ask of you, not just on the first day, but over the weeks that follow. Frequent visits can be a real commitment. Knowing the usual rhythm may help you plan transportation, work, and support at home.
For adults receiving Spravato for treatment-resistant depression, the FDA-labeled schedule has an initial induction phase followed by a maintenance phase. Your clinician adjusts the plan based on your response and tolerability; the schedule is not a promise that everyone will improve on the same timeline. This article focuses on how treatment is scheduled. For a brief overview of eligibility and the REMS program, see the practice's published guide “Is Spravato Safe? What to Know About Esketamine Side Effects, Monitoring, and Treatment Safety in New Haven”.
At Light-tunnel Behavioral Health Services Inc. in New Haven, Dr. Omolola Aragbada, PMHNP-BC, is one of the practice’s psychiatric providers. A provider can help you discuss depression treatment options and how medication management may fit into your care.
Spravato schedule: induction compared with maintenance
| Phase | Typical FDA-labeled schedule for adults with treatment-resistant depression | Main focus |
|---|---|---|
| Induction: weeks 1–4 | Twice weekly | Start treatment and assess benefit and tolerability |
| Maintenance: weeks 5–8 | Once weekly | Continue treatment and monitor symptoms and side effects |
| Maintenance: week 9 onward | Once weekly or once every two weeks | Individualize frequency to maintain response or remission |
The 2025 FDA prescribing information advises clinicians to assess benefit at the end of the four-week induction phase before deciding whether to continue. The appropriate dose and schedule depend on your clinical situation; do not change your dose or appointment frequency on your own. (FDA, 2025.)

What the weeks may look like
Weeks 1–4: Induction, twice each week
You’ll generally attend two supervised appointments per week during the first four weeks. At each visit, Spravato is self-administered under healthcare-provider supervision. Your care team monitors you after dosing, checks how you are feeling, and assesses safety.
The treatment itself is only one part of the visit. The FDA requires monitoring for at least two hours after each dose, including assessment for sedation, dissociation, respiratory depression, and changes in blood pressure. Arrange for someone to drive you home: you must not drive or operate machinery until the next day after a restful sleep. Ask your provider about preparation instructions, including food and drink restrictions before a session. (FDA, 2025.)
If you are still experiencing depression during this phase, that does not automatically mean treatment has failed. Your provider will consider your symptoms and functioning over time, along with side effects and other factors. In a 28-day randomized trial of adults with treatment-resistant depression, the group receiving esketamine plus a newly started antidepressant had greater average improvement in depression symptom scores by day 28 than the group receiving an antidepressant plus placebo nasal spray. That group result is not a guarantee of when, or whether, you personally will respond. (Popova et al., 2019.)
Weeks 5–8: Weekly maintenance
If treatment continues after induction, the labeled schedule generally changes to once weekly for weeks five through eight. This is less frequent than the initial phase, but still requires planning for an in-person session, observation, and a safe ride home.
Your provider will review how you are doing rather than relying on a single “good” or “bad” day. Depression symptoms can fluctuate, and improvement may include changes in daily functioning as well as mood. Tell your care team about new or worsening symptoms, side effects, or practical barriers that make it hard to attend.
Week 9 onward: An individualized interval
From week nine, the FDA-labeled schedule allows weekly or every-other-week treatment. The goal is to find the least frequent schedule that continues to maintain response or remission, with clinical reassessment, not to move everyone to every-other-week treatment on a fixed date. (FDA, 2025.)
The maintenance research helps explain why follow-up matters. In the randomized-withdrawal SUSTAIN-1 trial, participants first received esketamine with an oral antidepressant and entered the randomized phase only after achieving stable remission or response. Among those who had achieved stable remission, relapse occurred in 26.7% of participants who continued esketamine and 45.3% of those switched to placebo nasal spray while continuing the oral antidepressant. The results support ongoing clinical discussion for people who responded in the study; they do not establish that everyone needs Spravato indefinitely. (Daly et al., 2019.)

Spravato compared with typical oral antidepressant care
These are different treatment approaches, not interchangeable schedules. The right depression treatment options depend on your history, goals, health, and preferences.
| Consideration | Spravato treatment | Typical oral antidepressant care |
|---|---|---|
| How it is taken | Nasal spray self-administered under supervision in a certified healthcare setting | Usually taken at home on a regular prescribed schedule |
| Early schedule | Twice weekly for four weeks for the adult TRD schedule | Regular daily dosing is common; follow-up helps assess benefit and tolerability |
| Visit logistics | In-person appointment with at least two hours of monitoring after each dose | Medication-management visits may be less frequent, depending on your care plan |
| How to interpret timing | A structured induction phase is followed by reassessment and individualized maintenance | Response and adjustments vary; there is no one timeline that applies to everyone |
Some randomized trials studied esketamine alongside an oral antidepressant. The 2025 FDA label also includes use for adult treatment-resistant depression as monotherapy or with an oral antidepressant. Ask your prescriber which approach, if any, is appropriate for you. Clinical trial averages cannot predict an individual result. (FDA, 2025; Popova et al., 2019.)
An in-person Spravato appointment is required for administration and post-dose monitoring; telehealth cannot replace those parts of treatment. Some other mental health or medication-management visits may be offered by telehealth, depending on the service and practice arrangements. Confirm with the office which visit types are available.
Planning for visits, and what to ask
Twice-weekly appointments can affect work, caregiving, and transportation. Before starting, ask how scheduling works and make a practical plan for getting home after each session. If you miss a visit or cannot arrange transportation, contact your provider rather than trying to make up or change a dose yourself.
Consider asking:
- How will we track changes in mood and daily functioning?
- When will we review whether induction has helped enough to continue?
- Which side effects should I report promptly?
- What parts of care require an in-person appointment, and which may be available as a telehealth appointment?
- What happens if symptoms worsen or I have to miss a treatment?
At Light-tunnel Behavioral Health Services Inc., you can also ask about therapy, psychiatric evaluation, and medication management services as part of a personalized plan.
Self-pay clients: ask for a clear estimate
You can ask about the practice’s services even if you plan to pay out of pocket. Before scheduling, request a clear, itemized cost estimate and ask what it includes: evaluation, medication-management visits, treatment sessions, monitoring, and follow-up. If Spravato is being considered, ask specifically how medication and administration are billed, whether any fees are separate, and what costs may apply if treatment is not continued after induction. Insurance benefits and authorization rules vary; an estimate can help you plan without assuming coverage. For questions about available services or billing, contact the practice.
Medical disclaimer and crisis support
This article is for general education and is not a diagnosis or personal medical advice. Spravato has important risks and monitoring requirements and must be administered under supervision in a certified healthcare setting. A qualified provider can discuss the potential benefits, risks, and alternatives for your circumstances.
If you or someone else may be in immediate danger or needs urgent medical care, call 911 or go to the nearest emergency department. If you are in emotional distress or thinking about suicide, call or text 988 to reach the Suicide & Crisis Lifeline. If you can, tell someone you trust and do not wait for a routine appointment if you cannot stay safe.
References
- Daly EJ, Trivedi MH, Janik A, et al. “Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.” JAMA Psychiatry. 2019;76(9):893–903. PubMed
- Popova V, Daly EJ, Trivedi M, et al. “Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression.” American Journal of Psychiatry. 2019;176(6):428–438. PubMed
- U.S. Food and Drug Administration. SPRAVATO (esketamine) nasal spray: Prescribing Information. 2025. FDA label
Continue the Series
Do You Really Need Lifelong Spravato? Here’s the Truth About Esketamine Maintenance